Windtree Announces First Patient Enrolled in AEROSURF® Bridging Study for the Treatment of Respiratory Distress Syndrome
Windtree Therapeutics, Inc. (WINT)
Last windtree therapeutics, inc. earnings: 8/21 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
windtreetx.investorroom.com
Company Research
Source: PR Newswire
WARRINGTON, Pa., April 29, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced it has enrolled the first patient into its AEROSURF® phase 2b bridging study in premature infants with respiratory distress syndrome (RDS). This bridging study is intended to complete the phase 2 clinical program for AEROSURF and transition clinical development to phase 3 by validating the performance of the new aerosol delivery system (ADS) in the neonatal intensive care unit (NICU) and a more intensive dosing regimen. "Enrollment of the first patient in our phase 2b bridging study is an important step to build upon the positive results observed in the three previous AEROSURF phase 2 clinical trials," said Craig Fraser, Chief Executive Officer of Windtree. "If successful, this bridging study will validat
Show less
Read more
Impact Snapshot
Event Time:
WINT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WINT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WINT alerts
High impacting Windtree Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
WINT
News
- Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial DesignGlobeNewswire
- Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic ShockGlobeNewswire
- Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ETGlobeNewswire
- Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockGlobeNewswire
- Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic ShockGlobeNewswire
WINT
Sec Filings
- 10/9/24 - Form 4
- 10/4/24 - Form 8-K
- 10/1/24 - Form 8-K
- WINT's page on the SEC website